Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NON-REGULATORY PRESS RELEASE

Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website: https://meetings.asco.org/abstracts-presentations/232936

INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial evaluating the company’s therapeutic cancer vaccine candidate UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab as first-line treatment in unresectable or metastatic malignant melanoma. The trial was conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and enrolled 156 patients between June 2020 and July 2022.

The poster presentation features key findings and analyses after minimum 18-month follow up of the patients in the trial.

Presentation Details:

Abstract Number: LBA9519
Abstract Title: Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.

Session Title: Poster Session – Melanoma/Skin Cancers
Poster Board: 303
Date and Time: June 1, 2024, 1:30 PM – 4:30 PM (CT)
Presenter: Paul Lorigan, Professor of Medical Oncology at the University of Manchester and Investigator in the INITIUM study

Following the presentation, the poster will be available online in the Investor section of the Company’s website: https://ultimovacs.com/

==ENDS==

About Ultimovacs

Ultimovacs is a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines with broad applicability. Ultimovacs’ lead cancer vaccine candidate UV1 is directed against human telomerase (hTERT) an antigen which is present in 85-90% of cancers in all stages of tumor growth. A broad clinical program, with Phase II trials in five cancer indications enrolling more than 670 patients, aims to demonstrate UV1’s impact in combination with other immunotherapies in multiple cancer types expressing telomerase and where patients have unmet medical needs. UV1 is universal, off-the-shelf and easy to use, and is a patented technology owned by Ultimovacs.
In addition, Ultimovacs holds all rights of the proprietary TET technology platform for any possible future use of formulations in various solid tumor indications. The Company is listed on Euronext Oslo Stock Exchange (ULTI.OL).

For further information, please contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Anne Worsøe, Head of Investor Relations
Email: anne.worsoe@ultimovacs.com
Phone: +47 90686815

This stock exchange announcement was published by Anne Worsøe, Head of Investor Relations at Ultimovacs ASA, on June 1, 2024, at 14:15 CET.